Discover
FDA Drug Safety Podcasts
FDA investigating possible increased risk of death with lymphoma medicine Ukoniq (umbralisib)

FDA investigating possible increased risk of death with lymphoma medicine Ukoniq (umbralisib)
Update: 2022-02-09
Share
Description
Listen to an audio podcast of the February 3, 2022, FDA Drug Safety Communication, FDA is investigating a possible increased risk of death with the cancer medicine Ukoniq (umbralisib). We are re-evaluating this risk against the benefits of Ukoniq for its approved uses.
Comments
In Channel
00:00
00:00
x
0.5x
0.8x
1.0x
1.25x
1.5x
2.0x
3.0x
Sleep Timer
Off
End of Episode
5 Minutes
10 Minutes
15 Minutes
30 Minutes
45 Minutes
60 Minutes
120 Minutes



